Product Name: Clindamycin Phosphate Topical Lotion, 1%

Revision Date: 07.04.2022

Version No.: 00



| 1. IDENTIFICATION | |
|-------------------------------|---|
| Product Name | Clindamycin Phosphate Topical Lotion, 1% |
| Manufacturer Name | Encube Ethicals Pvt. Ltd. |
| Address | Plot No.C-1, Madkaim Industrial Estate Madkaim, Post- Mardol, Ponda Goa – 403 404, India. |
| Chemical name | L-threo-α-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6- [[1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]amino]-1-thio-,2- (dihydrogen phosphate), (2S-trans)-; |
| | Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2- pyrrolidinecarboxamido)1-thio-L-threo-α-D-galacto- octopyranoside 2- (dihydrogen phosphate) |
| Recommended use | Pharmaceutical product used as antibiotic agent indicated in the treatment of acne vulgaris |
| Restrictions on use | Use only as directed by the physician. |
| 2. HAZARD(S) IDENTIFICATION | |
| Appearance | This product is a white to off-white creamy liquid with a slight odor |
| Signal Word | WARNING |
| Statement of Hazard | Employees administering the product should not experience adverse effects if handled properly. The chief health hazard associated with exposure during normal use and handling is the potential for irritation of contaminated skin |
| Additional Hazard Information | |
| Short Term | May be harmful if swallowed. May cause skin irritation. Vapors irritating to eyes and respiratory tract. Breathing high vapor concentrations may cause central nervous system (CNS) depression resulting in dizziness, light-headedness, headache, nausea, and loss of coordination. Continued inhalation may result in unconsciousness and death. |
| Known Clinical Effects | Individuals who have had allergic reactions to products containing the active ingredient, Clindamycin Phosphate (or any other components of this product) may experience allergic reactions to this product. Use of the topical formulation of Clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use Page 1 of 8 |

Product Name: Clindamycin Phosphate Topical Lotion, 1%

Revision Date: 07.04.2022

Version No.: 00



of topical and systemic Clindamycin. See Section 11 (Toxicological Information) for additional information on possible adverse effects.

EU Indication of danger

EU Risk Phrases



Irritant

Flammability Hazards:If heated to high temperatures for a prolonged period, the water in this
product can evaporate off and the residue may ignite. When involved in
a fire, this material may decompose and produce irritating vapors and
toxic gases (e.g., carbon, nitrogen, phosphorus and sulfur oxides,
acrolein, and hydrogen chloride).Reactivity Hazards:This product is not reactive.NoteThis document has been prepared in accordance with standards for
workplace safety, which requires the inclusion of all known hazards of

the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

| 3. COMPOSITION / INFORMATION ON INGREDIENT | |
|--|---|
| Common name / Chemical name | Clindamycin Phosphate |
| CAS No. | 24729-96-2 |
| Concentration | 1% |
| Other Ingredients | Cetostearyl alcohol, Glycerin, Glyceryl Stearate SE, Isostearyl alcohol, Methyl paraben, Sodium Lauroyl Sarcosinate, Stearic acid, Purified water |
| 4. FIRST-AID MEASURES | |
| Inhalation | Remove to fresh air and keep patient at rest. If vapors of this product are inhaled, causing irritation, remove victim to fresh air. If necessary, use artificial respiration to support vital functions. Seek medical attention immediately. |
| Skin contact | Remove contaminated clothing and wash exposed area with soap and water. Obtain medical assistance if irritation occurs. |

Product Name: Clindamycin Phosphate Topical Lotion, 1%

Revision Date: 07.04.2022





| Eye contact | If this product contaminates the eyes, rinse eyes under gently running water. Use sufficient force to open eyelids and then "roll" eyes while flushing. Minimum flushing is for 20 minutes. The contaminated individual must seek medical attention if any adverse effect continues after rinsing. |
|--|---|
| Ingestion | If this product is swallowed, CALL PHYSICIAN OR POISON CONTROL CENTER FOR MOST CURRENT INFORMATION. If professional advice is not available, do not induce vomiting. Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately. |
| Most important symptoms/effects, acute and delayed | For information on potential signs and symptoms of exposure, see Section 2 - Hazards Identification and/or Section 11 - Toxicological Information. |
| 5. FIRE-FIGHTING MEASURES | |
| Extinguishing media | Use carbon dioxide, dry chemical, or water spray. |
| Specific hazards arising from the chemical | If heated to high temperatures for a prolonged period, the water in this product can evaporate off and the residue may ignite. When involved in a fire, this material may decompose and produce irritating vapors and toxic gases (e.g., carbon, nitrogen, phosphorus and sulfur oxides, acrolein, and hydrogen chloride). |
| Special protective equipment and precautions for fire-fighters | Incipient fire responders should wear eye protection. Structural firefighters must wear Self-Contained Breathing Apparatus (SCBA) and full protective equipment. If protective equipment is contaminated by this product, it should be thoroughly washed with running water prior to removal of SCBA respiratory protection. Firefighters whose protective equipment becomes contaminated should thoroughly shower with warm, soapy water and should receive medical evaluation if they experience any adverse effects. |
| 6. ACCIDENTAL RELEASE MEASURES | |
| | |

| Personal precautions, protective equipment, | Personnel involved in clean-up should wear appropriate personal |
|---|---|
| and emergency procedures | protective equipment (see Section 8). Minimize exposure. |
| Environmental Precautions | Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release. |
| Methods and materials for containment and | The product should be gently covered with absorbent pads. Clean spill |

Product Name: Clindamycin Phosphate Topical Lotion, 1%

Revision Date: 07.04.2022

Version No.: 00



| cleaning up | with pad and dispose of properly. Decontaminate the spill area (three times) using a bleach and detergent solution and then rinse with clean water. |
|--|--|
| Additional Consideration for Large Spills | Restrict access to the spill areas. For spills of amounts larger than 5 mL limit spread by gently covering with absorbent sheets, or spill-control pads or pillows. Be sure not to generate aerosols. The dispersion of aerosols into surrounding air and the possibility of inhalation is a serious matter and should be treated as such. Do not apply chemical inactivators as they may produce hazardous by-products. Thoroughly clean all contaminated surfaces three times using a bleach and detergent solution and then rinse with clean water. |
| 7. HANDLING AND STORAGE | |
| Precautions for safe handling | All employees who handle this product should be thoroughly trained to handle it safely. As with all chemicals, avoid getting this product ON YOU or IN YOU. Do not eat or drink while handling this product. Appropriate personal protective equipment must be worn (see Section 8, Engineering Controls and Personal Protection). Avoid generation of aerosols. |
| Conditions for safe storage | Containers of this product must be properly labeled. Store containers in a cool, dry location, away from direct sunlight and sources of intense heat. Recommended Storage Temperature: 20-25°C (68-77°F) [USP Controlled Room Temperature]. Protect from freezing. Store away from incompatible materials (see Section 10, Stability and Reactivity). Product should be stored in secondary containers. Keep containers tightly closed when not in use. |
| 8. EXPOSURE CONTROLS / PERSONAL PROTECTION | |
| Clindamycin Phosphate | 100 ug/m ³ TWA |
| Analytical Method | Analytical method available for clindamycin. Contact Encube Ethicals for further information. |
| Appropriate engineering controls | Use with adequate ventilation. Follow standard medical product handling procedures. During decontamination of work surfaces, workers should wear the same equipment recommended in Section 6 (Accidental Release Measures) of this MSDS. |
| Individual protection measures | Refer to applicable national standards and regulations in the selection |

and use of personal protective equipment (PPE).

Product Name: Clindamycin Phosphate Topical Lotion, 1%



Revision Date: 07.04.2022 **Version No.**: 00

| Respiratory protection | If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL. |
|------------------------|--|
| Skin protection | Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. |
| Eye protection | Wear safety glasses or goggles if eye contact is possible. |
| Hand | Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations. |

9. PHYSICAL AND CHEMICAL PROPERTIES

| Appearance | White to off-white lotion free from foreign particles |
|--|---|
| Odor threshold | Mild |
| Flash Point (Liquid) (°C) | Not applicable |
| Upper Explosive Limits (Liquid) (% by Vol.) | Not applicable |
| Lower Explosive Limits (Liquid) (% by Vol.) | Not applicable |
| рН | 4.0 - 7.0 |
| Viscosity | 20-500 ср |
| Specific Gravity | 0.90 -1.100 |
| 10. STABILITY AND REACTIVITY | |
| Reactivity | No data available. |
| Chemical stability | Stable under normal conditions of use. |
| Possibility of hazardous reactions | Will not occur. |
| Incompatible materials | This product is generally compatible with other common materials in a medical facility. Acids, strong oxidizers, water reactive materials, and other chemicals that could affect its performance should be avoided. |
| Hazardous decomposition products | Combustion: If exposed to extremely high temperatures, thermal decomposition may generate irritating fumes and toxic gases (e.g., carbon, nitrogen, phosphorus and sulfur oxides, acrolein, and hydrogen chloride). Hydrolysis: None known. |

Product Name: Clindamycin Phosphate Topical Lotion, 1%



Revision Date: 07.04.2022

Version No.: 00

| 11. TOXICOLOGICAL INFORMATION | |
|---|--|
| Information on Toxicological Effects General Information | The information included in this section describes the potential hazards of the individual ingredients |
| Short Term | Use of the topical formulation of Clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic Clindamycin. |
| Known Clinical Effects | Individuals who have had allergic reactions to products containing the active ingredient, Clindamycin Phosphate (or any other components of this product) may experience allergic reactions to this product. Use of the topical formulation of Clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic Clindamycin. |
| Acute Toxicity: (Species, Route, End | Clindamycin Phosphate |
| Point, Dose) | Rat Oral LD ₅₀ 1832 mg/kg |
| | Rat Para-periosteal LD ₅₀ 321mg/kg |
| | Rat Intraperitoneal LD ₅₀ 745mg/kg |
| | Mouse Oral LD ₅₀ 2359mg/kg |
| | Mouse Intravenous LD ₅₀ 820mg/kg |
| Irritation / Sensitization: (Study Type, | Clindamycin Phosphate |
| Species, Severity) | Eye Irritation (Rabbit) Moderate |
| | Skin Irritation (Rabbit) Mild |
| Repeated Dose Toxicity: (Duration, | Clindamycin Phosphate |
| Species, Route, Dose, End Point, Target Organ) | 6 Month(s) Rat Oral 600 mg/kg/day NOAEL No effects at maximum dose |
| | 6 Month(s) Dog Oral 600 mg/kg/day NOAEL Gastrointestinal system |
| Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s)) | Clindamycin Phosphate |
| | Prenatal & Postnatal Development Rat Subcutaneous 250 mg/kg NOAEL Not teratogenic |
| | Prenatal & Postnatal Development Rat Oral 300 mg/kg/day NOAEL |
| | Page 6 of 8 |

Product Name: Clindamycin Phosphate Topical Lotion, 1%



Version No.: 00



| | Not Teratogenic |
|---|--|
| | Prenatal & Postnatal Development Mouse Oral 600 mg/kg/day NOAEL Not Teratogenic |
| | Prenatal & Postnatal Development Rabbit Subcutaneous 5 mg/kg/day NOAEL Not Teratogenic, Maternal Toxicity |
| | Reproductive & Fertility Rat Oral 300 mg/kg/day NOAEL No effects at maximum dose |
| Genetic Toxicity: (Study Type, Cell Type/Organism, Result) | Clindamycin Phosphate |
| | Bacterial Mutagenicity (Ames) Salmonella Negative |

12. ECOLOGICAL INFORMATION

Environmental Overview

Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health, And Environmental Regulations/Legislation Text of R phrases and GHS Classification abbreviations Specific target organ toxicity, single exposure; Narcotic effects-Cat.3; H336 - May cause drowsiness and dizziness

Product Name: Clindamycin Phosphate Topical Lotion, 1%

Revision Date: 07.04.2022





| mentioned in Section 3 | Flammable liquids-Cat.3; H225 - Highly flammable liquid and vapor |
|------------------------|--|
| | Serious eye damage/eye irritation-Cat.2A; H319 - Causes serious eye irritation |
| | Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed |
| | Skin corrosion/irritation-Cat.3; H316 - Causes mild skin irritation |
| | Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction |
| | Xi - Irritant |
| | R10 - Flammable. |
| | R36 - Irritating to eyes. |
| | R43 - May cause sensitization by skin contact. |
| | R67 - Vapors may cause drowsiness and dizziness. |
| OSHA Label: | WARNING |
| | Flammable liquid and vapor. |
| | Causes eye irritation. |
| | Vapors may cause drowsiness and irritation of the eyes or respiratory tract |
| | May cause allergic reaction. |
| | |

16. OTHER INFORMATION

Contact Information

Encube Ethicals, Inc. 200 Meredith Avenue, Suite 101A, Durham, NC27713, USA https://www.encubeethicals.com/

Disclaimer: This material safety data sheet has been prepared for occupational exposure. Consumers: Refer to the package insert or product label for appropriate consumer-specific information about this product when used according to manufacturer's directions. Although reasonable care has been taken in the preparation of this document, we extend no warranties and make no representations as to the accuracy of the information contained therein, and assume no responsibility regarding the suitability of this information for the user's intended purposes or for the consequence of its use. Each individual should make a determination as to the suitability of the information for their particular purpose(s).

End of Safety Data Sheet